Synthesis and characterization of the radiopharmaceutical [18F]fluoroestradiol
DOI:
https://doi.org/10.15392/bjrs.v9i1A.1387Palavras-chave:
Radiopharmaceuticals, Breast Neoplasms, Product Synthesis, Quality ControlResumo
[18F]Fluoroestradiol ([18F]FES), an estrogen analog, may be used in Positron Emission Tomography (PET) for evaluation of the tumor cell receptor profile in a noninvasive way, which is an important factor for determining the therapy to be used, disease staging, prognosis and response to therapy in breast cancer. [18F]FES is a new radiopharmaceutical and does not have an official monograph in any pharmacopeia until now. Therefore, the objective of this work was the optimization of the [18F]FES automatic synthesis and the elaboration of an analytical protocol for final product analyses. Initially, the synthesis of [18F]FES was performed according to a modified commercial protocol, using a TracerLab MXFDG synthesis module specific for [18F]FES synthesis. New protocols for the physicochemical quality control assays of the radiopharmaceutical were developed, including pH, chemical purity, residual solvents, radiochemical identity and purity. Physicochemical and microbiological analysis were performed with the synthesized [18F]FES at different time points to evaluate its stability. The uncorrected synthesis yield was 18.37 ± 3.07 %. All Quality Control methodologies proved to be effective for the product. The physicochemical and microbiological results obtained in the stability study showed that [18F]FES is stable during 8 hours after its synthesis, even under stress conditions. At the end of the study, it was concluded that the [18F]FES complies with all specifications required for a radiopharmaceutical intended for diagnostic use.Downloads
Referências
INCA – Instituto Nacional do Câncer José Alencar Gomes da Silva. Estimativa 2014: Incidência de Câncer no Brasil. Rio de Janeiro: INCA, 2014.
FLANAGAN, F. L.; DEHDASHTI, F.; SIEGEL, B. A. PET in Breast Cancer. Semin Nucl Med, v. 28, p. 290-302, 1998.
SURTI, S. Radionuclide Methods and Instrumentation for Breast Cancer Detection and Diagnosis. Semin Nucl Med, v. 43, p. 271-280, 2013.
CHANG, J. M.; LEE, H. J.; GOO, J. M.; LEE, H.; LEE, J. J.; CHUNG, J.; IM, J. False Positive and False Negative FDG-PET Scans in Various Thoracic Diseases. Korean J Radiol, v. 7, p. 57-69, 2006.
LINDEN, H. M. L.; DEHDASHTI, F. Novel Methods and Tracers for Breast Cancer Imaging. Semin Nucl Med, v. 43, p. 324-329, 2013.
SUNDARARAJAN, L.; LINDEN, H. M.; LINK, J. M.; KROHN, K. A.; MANKOFF, K. A. 18F-Fluoroestradiol. Semin Nucl Med, v. 37, p. 470-476, 2007.
KNOTT, K. E. ; GRÄTZ, D. ; HÜBNER, S. ; JÜTTLER, S. ; ZANKL, C. ; MÜLLER, M. Simplified and automatic one-pot synthesis of 16α-[18F]fluoroestradiol without high-performance liquid chromatography purification. J Labelled Compd Radiopharm, v. 54, p. 749-753, 2011.
ACKERMANN, U. ; TOCHON-DANGUY, H.; PONIGER, S. ; DAVIS, I. ; SCOTT, A. Synthesis of F-18 Fluoroestradiol using the FlexLab Radiosynthesizer. Melbourne : iPhase Technologies, 2015. Available at: <https://www.iphase.com.au/assets/fes-flexlab.pdf>. Last accessed: 16 Jun. 2020.
DIXIT, M. ; SHI, J. ; WEI, L. ; AFARI, G. ; BHATTACHARYYA, S. Synthesis of Clinical-Grade [18F]-Fluoroestradiol as a Surrogate PET Biomarker for the Evaluation of Estrogen Receptor-Targeting Therapeutic Drug. Int J Mol Imaging, v. 2013, article ID 278607, 2013.
KUMAR, P. ; MERCER, J. ; DOERKSON, C. ; TONKIN, K. ; MCEWAN, A. J. B. Clinical production, stability studies and PET imaging with 16-α-[18F]fluoroestradiol ([18F]FES) in ER positive breast cancer patient. J Pharm Pharm Sci, v. 10, p. 256s-265s, 2007.
MORI, T. ; KASAMATSU, S. ; MOSDZIANOWSKI, C. ; WELCH, M. J. ; YONEKURA, Y. ; FUJIBAYASHI, Y. Automatic synthesis of 16α-[18F]fluoro-17β-estradiol using a cassette-type [18F]fluorodeoxyglucose synthesizer. Nucl Med Biol, v. 33, p. 281-286, 2006.
OH, S. J. ; CHI, D. Y. ; MOSDZIANOWSKI, C. ; KIL, H. S. ; RYU, J. S. ; MOON, D. H. The automatic production of 16α-[18F]fluoroestradiol using a conventional [18F]FDG module with a disposable cassette system. Appl Radiat Isot, v. 65, p. 676-681, 2007.
RÖMER, J. ; FÜCHTNER, F. ; STEINBACH, J. ; JOHANNSEN, B. Automated Production of 16α-[18F]Fluoroestradiol for Breast Cancer Imaging. Nucl Med Biol, v. 26, p. 473-479, 1999.
TEWSON, T. J. ; MANKOFF, D. A. ; PETERSON, L. M. ; WOO, I. ; PETRA, P. Interactions of 16α-[18F]-Fluoroestradiol (FES) with Sex Steroid Binding Protein (SBP). Mol Med Biol, v. 26, p. 905-913, 1999.
ZHOU, D. ; LIN, M. ; YASUI, N. ; AL-QAHTANI, M. H. ; DENCE, C. S. ; SCHWARZ, S. ; KATZENELLENBOGEN, J. A. Optimization of the preparation of fluorine-18-labeled steroid receptor ligands 16alpha-[18F]fluoroestradiol (FES), [18F]fluorofuranylnorprogesterone (FFNP), and 16beta-[18F]fluoro-5alpha-dihydrotestosterone (FDHT) as radiopharmaceuticals. J Labelled Compd Radiopharm, v. 57, p. 371-377, 2014.
KUNTZSCH, M. ; LAMPARTER, D. ; BRÜGGENER, N. ; MÜLLER, M. ; KIENZLE, G. J. ; REISCHL, G. Development and Successful Validation of Simple and Fast TLC Spot Tests for Determination of Kryptofix® 2.2.2 and Tetrabutylammonium in 18F-Labeled Radiopharmaceuticals. Pharmaceuticals, v. 7, p. 621-633, 2014.
BISPO, A. C. A. ; NASCIMENTO, L. T. C. ; COSTA, F. M. ; SILVA, J. B. ; MAMEDE, M. Development of an HPLC method for the radiochemical purity evaluation of [18F]fluoroestradiol. Braz J Radiat Sci, v. 7, p. 01-09, 2019.
UNITED STATES PHAMACOPEIAL CONVENTION. USP/NF 2020 – United States Phamacopeia/National Formulary, 43rd ed, Rockville : United States Pharmacopeia, 2020.
Downloads
Publicado
Edição
Seção
Licença
Direitos autorais (c) 2021 Brazilian Journal of Radiation Sciences
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Declaro que o presente artigo é original, não tendo sido submetido à publicação em qualquer outro periódico nacional ou internacional, quer seja em parte ou em sua totalidade. Declaro, ainda, que uma vez publicado na revista Brazilian Journal of Radiation Sciences, editada pela Sociedade Brasileira de Proteção Radiológica, o mesmo jamais será submetido por mim ou por qualquer um dos demais co-autores a qualquer outro periódico. Através deste instrumento, em meu nome e em nome dos demais co-autores, porventura existentes, cedo os direitos autorais do referido artigo à Sociedade Brasileira de Proteção Radiológica, que está autorizada a publicá-lo em meio impresso, digital, ou outro existente, sem retribuição financeira para os autores.
Licença
Os artigos do BJRS são licenciados sob uma Creative Commons Atribuição 4.0 Licença Internacional, que permite o uso, compartilhamento, adaptação, distribuição e reprodução em qualquer meio ou formato, desde que você dê o devido crédito ao (s) autor (es) original (is) e à fonte, forneça um link para a licença Creative Commons, e indique se mudanças foram feitas. As imagens ou outro material de terceiros neste artigo estão incluídos na licença Creative Commons do artigo, a menos que indicado de outra forma em uma linha de crédito para o material. Se o material não estiver incluído no licença Creative Commons do artigo e seu uso pretendido não é permitido por regulamentação legal ou excede o uso permitido, você precisará obter permissão diretamente do detentor dos direitos autorais. Para visualizar uma cópia desta licença, visite http://creativecommons.org/licenses/by/4.0/
